DIAGNOS - CEO, André Larente
CEO, André Larente
Source: La Presse
  • Medical technology company, DIAGNOS (ADK) has revealed a new service agreement with the Colombian Telemedicine Centre (CTMC)
  • The CTMC will use the company’s AI engine CARA to begin screening Colombia’s population for eye-related issues
  • CARA (Computer Assisted Retina Analysis) integrates with existing equipment, and makes standard retinal images sharper, clearer, and easier to read
  • The two parties plan to begin the screening project in two major regions of Colombia in the following weeks
  • Before the market opens, DIAGNOS (ADK) is trading at C$0.17 per share 

Medical technology company, DIAGNOS (ADK) has revealed a new service agreement with the Colombian Telemedicine Centre (CTMC).

The CTMC has chosen DIAGNOS and its artificial intelligence engine, CARA, for a screening project. In alliance with the country’s largest specialist centre, the CTMC will use CARA to screen Colombia’s population for eye-related issues.

The CTMC’s founder, Dr Jorge Alberto Velez B, said this will unburden the heavy costs of blindness caused by diabetes.

CARA (Computer Assisted Retina Analysis) is a tele-ophthalmology platform that integrates with pre-existing hardware or software. The tool’s image enhancement algorithms make standard images of a person’s retina sharper, clearer, and easier to read. 

CARA can process results at the point of care, which will empower local technicians. However, specialists will validate the automated results before scheduling follow-ups with patients requiring further treatment.  

The CTMC and DIAGNOS plan to start the screening project in two major regions of Colombia, in the coming weeks.

DIAGNOS’ President, André Larente, commented on the service agreement with Colombia’s Telemedicine Centre. 

“We would like to thank the CTMC for choosing our CARA platform. We believe that CARA is a perfect fit as the main engine of the telemedicine solution.

“After a successful eye screening program with Bayer in 2015, we return to Colombia to engage our AI service into a practical solution for the local community. Along with CTMC, we can add value by making our unique service accessible,” he said. 

Before the market opens, DIAGNOS (ADK) is trading at C$0.17 per share.

More From The Market Online

UniDoc brings AI to ER patients

UniDoc (CSE:UDOC) expands its AI partnership with DocBox, further integrating predictive analytics into emergency room operations.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.
labratory work

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

PharmaTher Holdings (CSE:PHRM) locks in its U.S. FDA-assigned goal date of abbreviated new drug application for Oct. 29, 2024.